Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26590306 | 1.00 | PDE10A (0.41) | PDE10AOPRK1KCNH2ALDH1A1LMNA | |
| SCHEMBL22712090 | 0.86 | ALDH1A1 (0.52) | OPRK1KCNH2ALDH1A1LMNAMAPT | |
| SCHEMBL30323005 | 0.86 | ALDH1A1 (0.52) | OPRK1KCNH2ALDH1A1LMNAMAPT | |
| SCHEMBL29970093 | 0.85 | GPR119 (0.40) | OPRK1KCNH2ALDH1A1GPR119MAPK1 | |
| SCHEMBL27154515 | 0.83 | OPRK1 (0.41) | OPRK1ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL29968748 | 0.83 | KCNH2 (0.41) | OPRK1KCNH2ALDH1A1LMNAMAPT | |
| SCHEMBL26590303 | 0.83 | KCNH2 (0.41) | OPRK1KCNH2ALDH1A1LMNAMAPT | |
| SCHEMBL26127556 | 0.82 | OPRK1 (0.39) | OPRK1ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL29503589 | 0.81 | GPR119 (0.46) | KCNH2ALDH1A1LMNAMAPTMET | |
| SCHEMBL28675410 | 0.81 | GPR119 (0.46) | KCNH2ALDH1A1LMNAMAPTMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | PDE10A 1423/4885OPRK1 3281/4885KCNH2 4535/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | PDE10A 1423/4885OPRK1 3281/4885KCNH2 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.